SCHEMBL4675822

SCHEMBL4675822

O=C(C=C(O)c1nc[nH]n1)c1cn(Cc2ccncc2)cc1CCc1ccccc1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 1/20 0.35
GPR52 Q9Y2T5 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
HCAR2 Q8TDS4 2/20 0.33
NR3C2 P08235 1/20 0.32
RAB9A P51151 1/20 0.32
HIF1A Q16665 2/20 0.31
KDM4E B2RXH2 1/20 0.31
KDR P35968 1/20 0.31
KDM5A P29375 1/20 0.30
KDM4C Q9H3R0 1/20 0.30
KDM5B Q9UGL1 1/20 0.30
CCNC P24863 1/20 0.30
CDK8 P49336 1/20 0.30
ALDH1A1 P00352 2/20 0.30
LMNA P02545 1/20 0.30
HPGD P15428 1/20 0.30
TSHR P16473 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675038 0.95 S1PR1 (0.32) SMN1; SMN2HCAR2NR3C2KDM5AKDM4C
SCHEMBL4676066 0.90 ALDH1A1 (0.36) GPR52SMN1; SMN2RAB9AALDH1A1HPGD
SCHEMBL4673650 0.90 MAOA (0.33) SMN1; SMN2RAB9AHIF1AALDH1A1TSHR
SCHEMBL4678111 0.90 CNR1 (0.34) HIF1AKDM4EKDM5AKDM4CKDM5B
SCHEMBL4676977 0.88 HCAR2 (0.33) HCAR2KDM4E
SCHEMBL5899400 0.88 CDK5 (0.41) ABCB1GPR52RAB9A
SCHEMBL4671926 0.88 LMNA (0.34) SMN1; SMN2HCAR2ALDH1A1LMNAHSD17B10
SCHEMBL4676558 0.88 ABCB1 (0.36) ABCB1GPR52SMN1; SMN2KDM4EKDM4C
SCHEMBL4676215 0.86 KDM4C (0.38) GPR52HCAR2NR3C2KDM4EKDM4C
SCHEMBL4670965 0.86 KDM4A (0.35) GPR52SMN1; SMN2NR3C2RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ABCB1 114/4885GPR52 2542/4885SMN1; SMN2 4107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.